Monopar Therapeutics (NASDAQ:MNPR) Now Covered by Analysts at Barclays

Key Points

• Barclays analysts initiated coverage on Monopar Therapeutics (NASDAQ:MNPR) with an "overweight" rating and set a price target of $125.00, indicating a potential upside of 22.49% from its previous close.
• The company reported earnings of ($0.35) EPS, exceeding analysts' expectations, and is projected to post -1.65 EPS for the current fiscal year.
• Insider activity revealed that major shareholder Tactic Pharma LLC sold over 550,000 shares in a transaction worth approximately $35 million, resulting in a significant decrease in their ownership stake.

Research analysts at Barclays began coverage on shares of Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) in a research report issued to clients and investors on Monday, MarketBeat reports. The firm set an "overweight" rating and a $125.00 price target on the stock. Barclays's price objective would suggest a potential upside of 22.49% from the company's previous close.

Other analysts have also recently issued research reports about the stock. Piper Sandler set a $95.00 price target on shares of Monopar Therapeutics and gave the stock an "overweight" rating in a research report on Thursday, September 25th. Oppenheimer set a $115.00 target price on shares of Monopar Therapeutics and gave the stock an "outperform" rating in a research report on Thursday, October 2nd. Lake Street Capital began coverage on shares of Monopar Therapeutics in a research report on Tuesday, September 23rd. They set a "buy" rating and a $106.00 target price on the stock. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Monopar Therapeutics in a research note on Wednesday, September 24th. Finally, HC Wainwright set a $105.00 price target on Monopar Therapeutics and gave the company a "buy" rating in a report on Monday, September 29th. Three analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Monopar Therapeutics has an average rating of "Buy" and an average price target of $105.67.

Monopar Therapeutics Trading Up 16.2%

Shares of MNPR opened at $102.05 on Monday. Monopar Therapeutics has a 12-month low of $4.50 and a 12-month high of $105.00. The firm has a 50-day moving average price of $55.33 and a 200 day moving average price of $43.76. The firm has a market capitalization of $629.65 million, a P/E ratio of -30.65 and a beta of 1.42.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last announced its quarterly earnings data on Tuesday, August 12th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.47) by $0.12. Equities research analysts predict that Monopar Therapeutics will post -1.65 earnings per share for the current fiscal year.

Insider Activity at Monopar Therapeutics

In other Monopar Therapeutics news, major shareholder Tactic Pharma Llc sold 550,229 shares of the business's stock in a transaction that occurred on Wednesday, September 24th. The stock was sold at an average price of $63.61, for a total transaction of $35,000,066.69. Following the transaction, the insider owned 272,026 shares of the company's stock, valued at $17,303,573.86. The trade was a 66.92% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 20.50% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Goldman Sachs Group Inc. acquired a new stake in Monopar Therapeutics during the 1st quarter worth about $673,000. AlphaQuest LLC bought a new stake in shares of Monopar Therapeutics in the 1st quarter worth approximately $44,000. OMERS ADMINISTRATION Corp purchased a new position in Monopar Therapeutics in the 1st quarter valued at approximately $328,000. Affinity Asset Advisors LLC purchased a new position in shares of Monopar Therapeutics during the 1st quarter valued at $2,257,000. Finally, Gerber LLC purchased a new position in shares of Monopar Therapeutics during the first quarter valued at about $204,000. 1.83% of the stock is currently owned by institutional investors.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.